Bristol-Myers Squibb will now challenge its rival, MSD's Keytruda, in second line lung cancer treatment in England after it agreed a 'managed access' deal with NICE.
Europe’s biggest cancer congress ESMO wraps up today, having delivering its fair share of major studies and talking points in cancer treatment over five days.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
